The company has signed a global licensing agreement with the contract research organization Eurofins BioPharma Product Testing Munich (Eurofins BPT Munich), to market the GARD test to its clients.
GARD is a genome-based test that gives the customers safety information whether chemical substances are at risk of causing allergies in humans.
Eurofins BioPharma Product Testing is the largest network of harmonized bio/pharmaceutical GMP/GLP product testing laboratories worldwide with 30 facilities all over the world, providing comprehensive laboratory services for the world’s major pharmaceutical, biopharmaceutical and medical device companies, according to the company. The Munich subsidiary of Eurofins BioPharma Product Testing was part of the ring trial in the validation of GARDskin, which was completed in the autumn of 2017.
An important stepping stone
Under the terms of the agreement, Eurofins BPT Munich will immediately include GARDskin and the add on test GARDpotency as a diagnostic tool in its chemical safety testing services to clients in the cosmetic, chemical and pharmaceutical industries worldwide.
“This new license agreement with such a major and strong partner provides an important stepping stone in the global marketing of GARD and it is also a hallmark of the high quality and relevance of GARD. We are very pleased to sign this important deal, in particular since Eurofins BPT Munich is a leading player in chemical safety testing, with a pronounced mission to contribute to global health and safety,” says SenzaGen’s CEO Anki Malmborg Hager.
Photo of Anki Malmborg Hager: Peter Hamlin/SenzaGen